Technical Analysis for MTNB - Matinas Biopharma Holdings, Inc.

Grade Last Price % Change Price Change
C 0.27 -9.17% -0.03
MTNB closed down 9.17 percent on Monday, March 18, 2024, on 53 percent of normal volume.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up

Date Alert Name Type % Chg
Inside Day Range Contraction 0.00%
Gapped Down Weakness 0.00%
Bullish Engulfing Bullish -9.17%
Crossed Above 20 DMA Bullish -9.17%
Crossed Above 200 DMA Bullish -9.17%
New Uptrend Bullish -9.17%
Expansion Pivot Buy Setup Bullish Swing Setup -9.17%
Pocket Pivot Bullish Swing Setup -9.17%
Volume Surge Other -9.17%
Wide Range Bar Range Expansion -9.17%

   Recent Intraday Alerts

Alert Time
Possible Inside Day about 10 hours ago
Gap Down Partially Closed about 14 hours ago
60 Minute Opening Range Breakdown about 14 hours ago
Down 5% about 14 hours ago
Gapped Down (Partial) about 15 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Matinas Biopharma Holdings, Inc. Description

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in identifying and developing therapeutics for the treatment of serious and life-threatening infections. It is engaged in developing a pipeline of product and development candidates, with an initial focus on serious fungal and bacterial infections. Its cochleate delivery technology platform is designed for the targeted delivery of pharmaceuticals directly to the site of infection or inflammation. Its MAT 2203 is an oral formulation of a spectrum anti-fungal drug called amphotericin B, which uses its cochleate delivery technology. Its MAT2501 is an orally administered, encochleated formulation of the spectrum aminoglycoside antibiotic amikacin, which may be used to treat different types of multidrug-resistant bacteria, including non-tubercular mycobacterial infections (NTM), as well as various multidrug-resistant gram negative and intracellular bacterial infections.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Pharmaceutical Drugs Inflammation Infection Antibiotics Bacterial Infections Antimicrobial Resistance Drug Resistance Aminoglycoside Multiple Drug Resistance

Is MTNB a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 0.8816
52 Week Low 0.1116
Average Volume 861,816
200-Day Moving Average 0.25
50-Day Moving Average 0.23
20-Day Moving Average 0.26
10-Day Moving Average 0.26
Average True Range 0.03
RSI (14) 54.95
ADX 25.04
+DI 28.66
-DI 18.42
Chandelier Exit (Long, 3 ATRs) 0.24
Chandelier Exit (Short, 3 ATRs) 0.28
Upper Bollinger Bands 0.30
Lower Bollinger Band 0.22
Percent B (%b) 0.64
BandWidth 29.04
MACD Line 0.01
MACD Signal Line 0.01
MACD Histogram -0.0005
Fundamentals Value
Market Cap 59.2 Million
Num Shares 217 Million
EPS -0.10
Price-to-Earnings (P/E) Ratio -2.73
Price-to-Sales 21.78
Price-to-Book 1.97
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.31
Resistance 3 (R3) 0.31 0.30 0.30
Resistance 2 (R2) 0.30 0.29 0.30 0.30
Resistance 1 (R1) 0.29 0.29 0.28 0.28 0.30
Pivot Point 0.28 0.28 0.28 0.28 0.28
Support 1 (S1) 0.26 0.27 0.26 0.26 0.25
Support 2 (S2) 0.26 0.26 0.25 0.24
Support 3 (S3) 0.24 0.26 0.24
Support 4 (S4) 0.24